Axel Hoos, M.D., Ph.D.
Senior Vice President, Therapeutic Area
Head for Oncology R&D
Dr. Hoos co-leads the oncology therapeutic area and builds the immuno-oncology portfolio of GlaxoSmithKline (GSK) across the modalities of antibodies, small molecules, biospecific molecules and cell and gene therapies, for which he directs discovery and development. Dr. Hoos also serves as interim chairman of the board of trustees of the Sabin Vaccine Institute, a Global Health organization; is a director on the board of Imugene, a biotech company; is co-director of the Cancer Immunotherapy Consortium; and is a scientific advisory board member of the Cancer Research Institute.
Dr. Hoos’ efforts in medicines development and global health focus on developing novel therapies for life-threatening diseases, scientific and procedural innovation, and collaboration across a broad range of constituents. Through his leadership, a new paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of immuno-oncology.
Prior to joining GSK, Dr. Hoos was the global medical lead in immunology-oncology at Bristol-Myers Squibb where he developed Yervoy (Ipilimumab; anti CTLA-4), the first successful therapy in immuno-oncology. He was also senior director of clinical development at Agenus Bio, previously Antigenics, a biotech company.
Dr. Hoos holds an M.D. from Ruprecht-Karls-Universitat in Heidelberg and a Ph.D. in molecular oncology from the German Cancer Research Center. He trained in surgery at the Technical University in Munich, and trained further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.